Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells-Reference-Cited by-同舟云学术

Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells

Published:2017-02-28 Issue:7 Volume:1 Page:468-476
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Aihara Ayako¹,Koike Tomo²,Abe Natsuki¹,Nakamura Sou²,Sawaguchi Akira³,Nakamura Takanori¹,Sugimoto Naoshi²,Nakauchi Hiromitsu⁴,Nishino Taito¹,Eto Koji²⁵

Affiliation:

1. Biological Research Laboratories, Nissan Chemical Industries Ltd., Saitama, Japan;

2. Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan;

3. Department of Anatomy, Miyazaki University Faculty of Medicine, Miyazaki, Japan;

4. Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; and

5. Department of Regenerative Medicine, Chiba University Graduate School of Medicine, Chiba, Japan

Abstract

Key Points TA-316, a novel CMA, enhances human platelet ex vivo generation from iPS cells. TA-316 exhibited biased megakaryopoiesis at levels comparable to rhTPO and superior to eltrombopag.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/7/468/878202/advances000844.pdf

Reference23 articles.

1. Overview of blood components and their preparation;Basu;Indian J Anaesth,2014

2. Platelet transfusion - the art and science of compromise;Cid;Transfus Med Hemother,2013

3. Diagnosis and management of refractoriness to platelet transfusion;Schiffer;Blood Rev,2001

4. Hematopoietic stem cell expansion: challenges and opportunities;Walasek;Ann N Y Acad Sci,2012

5. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells;Takayama;J Exp Med,2010

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mass production of iPSC-derived platelets toward the clinical application;Regenerative Therapy;2024-03

2. Ex Vivo Production of Platelets From iPSCs: The iPLAT1 Study and Beyond;HemaSphere;2023-05-17

3. Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets;International Journal of Hematology;2022-12-27

4. Production and nonclinical evaluation of an autologous iPSC–derived platelet product for the iPLAT1 clinical trial;Blood Advances;2022-12-13

5. iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study;Blood;2022-12-01